UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) ~~December 29~~April 7, 2016 ~~2015~~

SCIENCE TO CONSUMERS, INC.
(Exact name of registrant as specified in its charter)

Nevada	333-~~185928~~190391	33N33-1227949
(State or other jurisdiction of	(Commission File Number)	(IRS Employer
incorporation)		Identification No.)

Faraday Str. 31, Leipzig, Germany	04159
(Address of principal executive offices)	(Zip Code)

Registrant’s telephone number, including area code 49 (0)~~1738264717~~ 1738264717

N/A (Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

[ ] Written communications pursuant to Rule ~~425~~ 425 under the Securities Act (17 CFR 230.425) ~~[ ] Soliciting material~~ pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a -12)[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d -2(b)) [ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e -4(c))

Item 1.01	Entry into a Material Definitive Agreement
Item 3.02	Unregistered Sales of Equity Securities

[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a -12)

~~Effective~~[ ] Pre-commencement ~~December~~communications ~~29, 2015, we entered into an exclusive license agreement with Biomatrix Inc., a Delaware corporation,~~ pursuant ~~to which~~ ~~we obtained the exclusive rights~~ to ~~sell~~Rule ~~certain~~14d-2(b) ~~proprietary~~under ~~skincare products of Biomatrix by direct to consumer marketing and sales in~~ the ~~territories~~Exchange ~~of China~~Act ~~and~~(17 ~~Europe.~~CFR In consideration for the marketing, sales and distribution services to be provided by our company, Biomatrix has agreed to supply product inventory at a rate not less favorable than that provided to any third party240. ~~Additionally,~~14d Biomatrix has agreed to transfer to our company 100% equity ownership of Biomatrix Inc., an Arizona corporation which holds all right and title to the product distribution rights acquired. In consideration of transfer of title and rights acquired, we agreed to issue to Biomatrix -2(~~Delaware~~b) ~~2,000,000~~) ~~restricted common shares in the capital stock of our company.~~

~~The~~[ ] Pre-commencement ~~initial~~communications ~~term of the exclusive license agreement is for 5~~pursuant ~~years, subject~~ to ~~our~~Rule ~~company~~13e-4(c) ~~achieving~~under ~~minimum sales of $250,000 and $500,000 during~~ the ~~first~~Exchange ~~and~~Act ~~second~~(17 ~~years~~CFR ~~of the agreement, respectively~~240.13e Thereafter, the term will automatically renew for successive 5 year periods provided that we achieve a minimum $500,000 in sales of the licensed products during each calendar year of the term, excluding the first year.-4(c))

~~Closing~~Item ~~of the transaction is subject to completion of due diligence and to the transfer of the Biomatrix, Arizona securities to our Company~~4.01 ~~Biomatrix~~Changes ~~Arizona~~in ~~will~~Registrant’s ~~become~~Certifying ~~our wholly owned subsidiary upon completion of the transaction.~~Accountant

2(a) Previous independent registered public accounting firm

~~Pursuant~~(i) toOn ~~the~~April ~~exclusive~~7, ~~license~~2016, ~~agreement~~KLJ & Associates, weLLP ~~issued~~resigned ~~an aggregate~~as our independent registered public accounting firm. (ii) The reports of 2KLJ & Associates,~~000~~ LLP on our financial statements as of and for the fiscal years ended May 31,~~000~~ ~~common~~2015 ~~shares~~and 2014 contained no adverse opinion or disclaimer of opinion and were not qualified or modified as to ~~one~~uncertainty, audit scope or accounting principle except to indicate that there was substantial doubt about our ability to continue as a going concern. (1iii) ~~person~~Our ~~relying~~Board of Directors participated in and approved the decision to change independent registered public accounting firms. (iv) During the fiscal years ended May 31, 2015 and 2014, there have been no disagreements withKLJ & Associates, LLP on any matter of accounting principles or practices, financial statement disclosure or auditing scope or procedure, which disagreements if not resolved to the ~~exemption from~~satisfaction ~~registration~~KLJ ~~for~~& ~~“accredited~~Associates, ~~investors”~~LLP ~~contained~~would have caused them to make reference thereto in ~~Rule~~connection ~~506~~with oftheir ~~Regulation D~~report ofon the ~~Securities~~financial ~~Act~~statements offor ~~1933.~~such years.

~~Item~~(v) 9We have requested that KLJ & Associates, LLP furnish us with a letter addressed to the SEC stating whether or not it agrees with the above statements.01 ~~Financial~~A ~~Statements~~copy ~~and~~of ~~Exhibits~~the letter provided by KLJ & Associates, LLP is filed as Exhibit 16.1 to this Current Report on Form 8-K.

~~10.1~~(b) ~~Exclusive~~New ~~License~~independent ~~Agreement~~registered ~~dated~~public ~~December~~accounting ~~16, 2015 between the Company and Biomatrix Inc.~~firm

3(1) On April 25, 2016, the Company engaged Yichien Yeh, CPA as its new independent registered public accounting firm. During the two most recent fiscal years, the Company had not consulted with Yichien Yeh, CPA regarding any of the following:

	(i)	the application of accounting principles to a specific transaction, either completed or proposed;

	(ii)	the type of audit opinion that might be rendered on our financial statements, and none of the following was provided to the Company: (a) a written report, or (b) oral advice that Yichien Yeh, CPA concluded was an important factor considered by us in reaching a decision as to accounting, auditing or financial reporting issue; or

	(iii)	Any matter that was subject of a disagreement, as that term is defined in Item 304(a)(1)(iv) of Regulation S-K.

Item 9.01	Financial Statements and Exhibits

16.1	Letter from KLJ & Associates, LLP.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

SCIENCE TO CONSUMERS, INC. /s/ Edwon Lam Edwon Lam Principal Executive Officer April 26, 2016

/s/ Edwon Lam Edwon Lam Chief Executive Officer

Date: January 6, 2016

Filing Compare · Science to Consumers, Inc.